Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 21;107(3):617–627. doi: 10.1002/cpt.1665

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Actionable phenotypes. (a) Actionable phenotypes of the entire cohort, (b) the retrospective cohort, and (c) the prospective cohort. Red: actionable; gray: not actionable. (d) The total number of actionable phenotypes per individual. Actionable is classified as: any phenotype with a dosing advice available in the Dutch Pharmacogenetics Working Group guidelines. An unknown phenotype is categorized as not actionable. Results are based on all genotypes with sufficient coverage (haplotype quality > 20). *Due to an inability to call copy number variants, only CYP2D6 diplotypes consisting of two null‐alleles were assigned a phenotype (poor metabolizer), no phenotype was assigned for other phenotypes classifying them as unknown. ^†CYP2C19 phenotypes could not be determined for any of the individuals in the prospective cohort due to a lack of coverage for one of the variants.